Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
Date:10/21/2011

the company and its product pipeline to investors on a conference call. To participate in the conference call, please call one of the following telephone numbers 15 minutes prior to the event, using access code 6749807: +31(0)20-721-9158 for the Netherlands and +44(0)20-3450-9987 for the UK. Following the presentation, the lines will be opened for questions. A replay of the call will be available following the event.

About Glybera®

AMT has developed Glybera as a treatment for patients with the genetic disorder lipoprotein lipase deficiency. LPLD is an orphan disease for which no treatment exists today. The disease is caused by mutations in the LPL gene, resulting in highly decreased or absent activity of LPL protein in patients. This protein is needed in order to break down large fat-carrying particles that circulate in the blood after each meal. When such particles, called chylomicrons, accumulate in the blood, they may obstruct small blood vessels. Excess chylomicrons result in recurrent and severe acute inflammation of the pancreas, called pancreatitis, the most debilitating and life-threatening clinical complication of LPLD. Glybera® has orphan drug status in the EU and US.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. In addition to Glybera, AMT has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 ... has announced the addition of the  "The ... Other 2-D Nanomaterials "  report to their ... ,CNTs and graphene are the strongest, lightest ... with a performance-per-weight greater than any other ...
(Date:10/22/2014)... The North American crystal oscillator market report ... analysis and forecast of revenue. This market was valued ... reach $623.6 million by 2018, at a CAGR of ... TOC of the North American crystal oscillator market report, ... This also provides a glimpse of the segmentation of ...
(Date:10/22/2014)... 2014 Grace Century, a private equity ... announces the addition of Dr. Yousef “Josh” Siddiqui ... team. Dr. Siddiqui will provide further healthcare expertise to ... of University College Medical School in the ... in 2001. With further certification as a General Practitioner ...
(Date:10/22/2014)... Nuvilex, Inc. (OTCQB: NVLX) – According to ... are living with diabetes, with  that number expected to ... market for diabetes treatments is approximately $500 billion.  ... from pancreatic cancer.  Pancreatic cancer is the fourth most ... the United States , and according to ...
Breaking Biology Technology:The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... Phosphatase useful for dephosphorylation serine,threonine or tyrosine ... Mary Ellen Simcox ,Stratagene Cloning Systems, Inc. ... dualspecificity protein,phosphatase that has been produced as ... calmodulinbinding peptide. The tag simplifies purification of ...
... polymerase delivers high fidelity and great,performance ... Holly Hogrefe ,Stratagene , Stratagene has ... novel enzyme formulation that provides,superior performance in ... that Herculase enhanced DNA polymerase is even ...
... Generate cDNA libraries with as little as 50 ng ... Tanya Hosfield ,Marie Callahan ,John C. Bauer Mike ... Lenhart Paul Young ,Human Genome Sciences, Rockville, Maryland , ... new method to generate high-efficiency cDNA libraries in a plasmid,vector. ...
Cached Biology Technology:Highly Active and Removable AffinityTagged Lambda Phosphatase 2Highly Active and Removable AffinityTagged Lambda Phosphatase 3Highly Active and Removable AffinityTagged Lambda Phosphatase 4Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 2Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 3Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 4Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 5Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 6Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 7Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 8Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 9Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 10Constructing Directional cDNA Libraries from Limited Amounts of RNA 2Constructing Directional cDNA Libraries from Limited Amounts of RNA 3Constructing Directional cDNA Libraries from Limited Amounts of RNA 4Constructing Directional cDNA Libraries from Limited Amounts of RNA 5Constructing Directional cDNA Libraries from Limited Amounts of RNA 6Constructing Directional cDNA Libraries from Limited Amounts of RNA 7
(Date:10/18/2014)... 2,000 patients referred for evaluation of suspected genetic ... for 25 percent, including detection of a number ... to disease, according to a study appearing in ... to coincide with the American Society of Human ... exons or coding regions of thousands of genes ...
(Date:10/17/2014)... knowledge regarding Ebola is critical and pertinent for practicing ... global outbreak and epidemic. The Journal, Disaster Medicine ... issue, Ebola Virus and Public Health, to surround the ... this critical societal moment. , On October 17, ... Clinicians . The primer was prepared by Dr. Eric ...
(Date:10/17/2014)... of Copenhagen have shown for the first time how ... fibrosis patients, giving them the opportunity to get tremendous ... , The study also discovered the bacterial growth in ... halted or slowed down by the immune cells. The ... and helped "suffocate" the bacteria, forcing the bacteria to ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... MADISON, WI, MARCH 1, 2011 Methane ... permafrost, termites, oceans, freshwater bodies, non-wetland soils, are all ... methane presence ca n be accredited to human-related activities. ... burning, waste management and animal husbandry. The release of ...
... available in Spanish . , Those who ... and teas may tend to overlook the benefits of drinking ... Agricultural Research magazine, the idea that herbal teas may provide ... U.S. Department of Agriculture (USDA)-funded scientists in Boston, Mass., ...
... release is available in Spanish . ... (UPV/EHU), has developed genetic-molecular tools, with the intention of completing ... equine breeds in the Basque Country Autonomous Community (CAPVEAE) and ... DNA sequence) and certain SNPs (a kind of variation in ...
Cached Biology News:Measuring methane 2Don't underestimate the power of herbal teas 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 3
... I can be used in intracellular staining ... cells and to serve as an antibody ... cell permeabilization is a reversible process, it ... the presence of saponin during intracellular staining. ...
... raised against a partial recombinant ... PPP4C (NP_002711, 218 a.a. ... protein with GST tag. ... NM_002720 Protein ...
... Eppendorf Thermomixer R offers maximum application ... shaking, heating, and cooling. Its active ... application and temperature control ranges. Five ... 24 micro test tubes, are available ...
Mouse monoclonal antibody raised against a partial recombinant PDE2A. NCBI Entrez Gene ID = PDE2A...
Biology Products: